Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 15 results for bupropion

  1. Dupilumab for treating prurigo nodularis [ID4054]

    In development [GID-TA11081] Expected publication date: 13 March 2024

  2. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

  3. Tobacco: treating dependence (QS207)

    This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.

  4. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.

  5. Varenicline for smoking cessation (TA123)

    Evidence-based recommendations on varenicline (Champix) for adults who want to stop smoking.

  6. Psychosis and schizophrenia in adults (QS80)

    This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.

  7. Psychosis and schizophrenia in adults: prevention and management (CG178)

    This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.

  8. Lung cancer in adults (QS17)

    This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.

  9. Past appeals and decisions

    30 September 2016 TA494 Obesity (prolonged-release) - naltrexone-bupropion 12 December 2017 TA621 Osimertinib for untreated EGFR-positive

  10. Innovative ways to support smokers requiring nicotine management in a mental health organisation

    nicotine replacement products, inclusive of the option for varenicline and bupropion Identify service users and carers wishing to...

  11. Familial hypercholesterolaemia: identification and management (CG71)

    This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.

  12. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

  13. Obesity: identification, assessment and management (CG189)

    This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.

  14. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10

  15. Methods for the development of NICE public health guidance (third edition) (PMG4)

    Methods for the development of NICE public health guidance (third edition)